

March 30, 2023

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: European Union Good Manufacturing Practice (EU GMP) Pre-Audit has been conducted at manufacturing site situated at Surat Special Economic Zone**

**Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject and further to our letter dated March 16, 2023; we, Zota Health Care Limited (the “Company”) are delighted to inform you that the EU GMP Pre-Audit has been conducted by the European Union Good Manufacturing Practice at Surat Special Economic Zone Site from March 27, 2023 to March 29, 2023 and the inspection report on the same is awaited from the said regulatory authority; on receipt of the inspection report, we shall intimate the same to you in due course of time.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
Place: Surat

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352